January 2026 Research Update

This group of studies highlights that symptoms resembling multiple system atrophy (MSA), especially when balance and coordination problems are prominent, can also come from different causes such as inherited conditions or immune-related disease. Overall, the papers point to the value of carefully separating MSA from lookalike conditions using a mix of clinical follow-up, genetic testing, and selected blood and brain scan markers, while recognizing that many of these signals are still early-stage and uncommon. [1] [2] [3] [4]

In a report of two first cousins first labeled as having MSA, whole-genome sequencing changed the diagnosis for one cousin to late-onset metachromatic leukodystrophy (MLD) due to two ARSA gene changes, meaning the family did not share a single inherited cause of MSA. The other cousin did not have the same genetic cause identified, even though their symptoms had overlap with MSA (including low blood pressure on standing and coordination problems). Because this describes two related individuals, it shows how convincing a lookalike can be but does not tell how often this occurs. [1]

Another single-patient report described an inherited ataxia called spinocerebellar ataxia type 41 (SCA41) that was initially interpreted as the cerebellar type of MSA (MSA-C). Whole-exome sequencing identified a TRPC3 gene change (p.K652R), showing that a genetic ataxia can be mistaken for MSA-C when symptoms mainly involve unsteady walking. As a one-person report, it expands the list of possible lookalikes but cannot estimate how common this specific cause is. [2]

A larger retrospective study followed 45 people diagnosed with idiopathic late-onset cerebellar ataxia (meaning a later-life ataxia without a known cause at first) for about 5.7 years and found that 13 later developed MSA-C. Those who converted had more severe ataxia at the start and showed smaller pons and certain connecting nerve-bundle regions on baseline MRI, plus lower measures of tissue organization in key cerebellar pathways, suggesting some brain scan patterns may appear before MSA-C is clinically clear. This was an observational study, so it identifies patterns linked to later diagnosis but does not prove cause. [3]

In a biomarker discovery study that screened blood samples, researchers identified a rare autoantibody (TMEM132A-IgG) in 2 of 436 people evaluated for autoimmune cerebellar ataxia and in none of several comparison groups, including people with MSA-C. The two antibody-positive patients had progressive cerebellar ataxia with additional nerve-system signs and distinct spinal fluid and MRI features, suggesting a possible immune-related ataxia subtype that could be considered among MSA lookalikes. Because only two patients were identified, it remains uncertain how often this antibody appears and how specific it is across different neurologic diseases. [4]

For patients and caregivers, these studies reinforce that when symptoms look like MSA (especially progressive balance and coordination problems, sometimes with autonomic symptoms), the underlying cause can still differ, including genetic or immune-related conditions that may not be obvious early on. The imaging study suggests some brain scan measurements might help identify people whose undefined late-onset ataxia later becomes clearly MSA-C, but this is based on one center's retrospective follow-up. The genetic and antibody papers are mainly background research for refining diagnosis, since they describe rare situations (single families or a handful of antibody-positive cases) and do not yet show how often these explanations apply in everyday care. [1] [2] [3] [4]

Across these papers, the overall pattern was that no single test is enough on its own, but combining careful clinical evaluation with selected lab or imaging measures may improve how confidently multiple system atrophy (MSA) is distinguished from Parkinson's disease and other similar conditions. Several approaches showed measurable differences in MSA compared with healthy people, and a few were designed specifically to help separate MSA from other alpha-synuclein conditions. Most studies were cross-sectional (a snapshot in time), so it remains uncertain how early these measures change or how well they perform across different clinics. [5] [6] [7] [8] [9] [10] [11] [12]

In a prospective registry follow-up, updated 2022 diagnostic criteria increased specificity (fewer false positives) compared with older criteria, and spinal fluid markers helped separate MSA from Parkinson's disease and other mimics. In that same work, a spinal fluid alpha-synuclein seeding test was negative in confirmed MSA and positive in a few cases that were later considered Parkinson's disease, while higher spinal fluid neurofilament light chain levels were seen in MSA and linked to higher risk of death. [5]

Several imaging and digital testing approaches aimed to capture MSA-related changes in the brain and movement control. A brain scan study reported that a serotonin-transporter signal pattern in the brainstem (lower in midbrain and higher in pons) separated the MSA-P subtype from healthy controls, and a small set of autopsy results supported the same pattern in brain tissue. [10]

Other imaging work suggested markers that may reflect disease burden rather than diagnosis against other conditions. One MRI and PET study found the choroid plexus (a structure involved in making cerebrospinal fluid) was smaller in MSA than in healthy controls and tracked with cerebellar size and brainstem/cerebellar metabolism, but it did not track with a motor symptom severity scale in that dataset. [7]

A virtual-reality eye movement test found that people with MSA had worse smooth pursuit and slower eye movement speeds than healthy controls, and a combined metric separated MSA from controls with moderate accuracy. The eye movement measures also related to overall clinical severity and thinking test scores, and to structural brain changes in the cerebellum and frontal areas on MRI. [11]

Eye imaging (optical coherence tomography) showed that several retinal layers were thinner in MSA, Parkinson's disease, and progressive supranuclear palsy than in healthy controls, but the patterns had limited ability to cleanly separate Parkinson's disease from atypical parkinsonism. In this study, a layer called the ganglion cell-inner plexiform layer was reduced in Parkinson's disease and progressive supranuclear palsy but not in MSA, while nerve fiber layer thinning was seen across patient groups. [9]

Sleep-based heart rhythm measures and newer tissue or blood tests were also explored as biomarkers related to alpha-synuclein diseases. In an overnight sleep study that included MSA among other alpha-synuclein conditions, heart rate variability was lower than in controls, especially during non-REM sleep, suggesting reduced nighttime parasympathetic activity. [8]

Two studies examined alpha-synuclein biology in ways that could eventually support differential diagnosis, though they were not standard clinical tests. One autopsy skin study showed that skin samples from Parkinson's disease, dementia with Lewy bodies, and MSA could seed alpha-synuclein in a lab assay, and the resulting aggregate features differed by disease, suggesting disease-specific "strains" may be detectable in skin. [6]

A translational study combining human tissue, mouse, and cell work linked MSA to iron-driven cell death in oligodendrocytes and tested a blood-based measure using oligodendrocyte-derived extracellular vesicles. In their plasma samples, this vesicle measure was lower in MSA than in Parkinson's disease or healthy controls, with moderate diagnostic accuracy reported, but this approach remains research-stage. [12]

For patients and caregivers, these studies reflect active work on tests that could support diagnosis when symptoms overlap with Parkinson's disease or other parkinsonian disorders, using spinal fluid, imaging, eye movement testing, sleep physiology, and experimental skin or blood assays. Right now, much of this evidence is still based on single-center or cross-sectional studies, and some methods rely on specialized equipment or research-only lab techniques, so it is uncertain how consistently they will work across different hospitals or at very early stages. The most immediately applicable message is that updated clinical criteria plus supportive biomarkers can improve diagnostic confidence in research and specialty settings, while newer blood and skin approaches are still being developed and validated. [5] [6] [10] [11] [12]

This month, studies pointed to two connected ideas: (1) multiple system atrophy (MSA) may not progress the same way for everyone, and (2) measurable changes in walking and speech can help describe how the disease is affecting daily life over time. The clearest survival signal came from an autopsy-based subtype in which two brain systems were heavily involved early, and this subtype also had more early falls. [13] [14] [15]

In an autopsy-confirmed study of 167 people with MSA, researchers used a machine-learning approach to group people by where nerve cell loss was most prominent across five brain regions. They identified three subtypes, and the group with early, simultaneous involvement of both the substantia nigra and the olivopontocerebellar system had worse survival than the other two subtypes. [13]

The same autopsy-based subtype also had faster clinical worsening and more early falls than the other subtypes, matching the idea that broader early brain involvement can show up as earlier balance and walking problems. Tissue staining supported that this subtype had more widespread alpha-synuclein buildup in both systems. [13]

Movement monitoring suggested that both clinic-based walking tests and at-home wearable sensors capture different parts of mobility change in MSA. In a multicenter study (23 MSA, 20 progressive supranuclear palsy, 41 Parkinsons disease), people with MSA and progressive supranuclear palsy generally walked more slowly with shorter steps in the clinic and also took fewer steps and spent less time in moderate-to-vigorous activity at home than people with Parkinsons disease. [14]

Speech tracking added a narrower but practical clue about communication: in a small retrospective study of 21 adults with spinocerebellar degeneration or MSA, overall speech muscle control worsened over about 31 months. Measures related to the larynx (voice box) were the only scores that predicted how understandable speech was, while palate function was relatively preserved. [15]

For patients and caregivers, these studies mainly help explain why progression can look different across people with MSA and why certain problems (especially early falls, reduced real-world mobility, and voice-related speech changes) may track with more significant disease impact. The subtype and survival results come from autopsy-confirmed data and describe group patterns rather than a tool currently used in routine care, while the walking and speech measures are still exploratory and were studied in small or mixed groups. What remains uncertain is how well these monitoring approaches can predict an individual persons future course, and which measures are most reliable across different settings and stages.

Across this month's treatment and supportive care research, the clearest evidence came from a retrospective international study of feeding tube placement in people with swallowing difficulties. It suggested longer survival after swallowing problems began, while the impact on aspiration pneumonia was unclear. A separate single-patient report described symptom relief after an acupuncture approach, but this kind of evidence cannot show how well it works for most people. [16] [17]

In a 72-person international cohort that included multiple system atrophy (MSA) as well as other atypical parkinsonian syndromes, people who received a percutaneous endoscopic gastrostomy (PEG) feeding tube had longer median survival from the onset of swallowing difficulty than those who did not receive PEG. However, PEG was not clearly linked to fewer hospital admissions for aspiration pneumonia, meaning breathing-in food or liquid may still occur even with tube feeding. [16]

One case report described a person with MSA and autonomic dysfunction who received a combined acupuncture approach (Sun s scalp acupuncture with yinyang needling). The report stated symptoms improved after 4 weeks and the person remained stable at a 4-week follow-up, but it did not show whether similar results would happen in other patients. [17]

For patients and caregivers, these studies mainly add background information for discussions about supportive care when swallowing and nutrition become difficult in MSA. The feeding tube study suggests survival may be longer in people who get a PEG after swallowing problems start, but it does not settle whether PEG reduces aspiration pneumonia risk, and it included several related diagnoses rather than MSA alone. The acupuncture report is limited to one person, so it is too early to know how broadly it applies, what symptoms it helps most, or how long benefits might last. [16] [17]

Across these studies, researchers focused on why multiple system atrophy (MSA) damages brain circuits by looking beyond neurons alone. The overall pattern was that alpha-synuclein biology and the brain's immune-like signaling may directly affect oligodendrocytes (cells that help insulate nerve fibers with myelin), and that other brain barrier-related cells may show metabolic changes in neurodegeneration. Most of the evidence here is exploratory and comes from lab models or postmortem tissue, so it helps explain possible disease pathways rather than proving what drives symptoms in living people.

In mouse and cell experiments designed to model MSA-like changes, blocking a receptor called toll-like receptor 2 (TLR2) reduced alpha-synuclein build-up inside oligodendrocytes (the type of clumps that resemble MSA glial cytoplasmic inclusions). This was linked to less inflammation in brain tissue, less myelin damage, and better movement in the mice, suggesting TLR2 signaling may be one route by which alpha-synuclein effects spread from neurons to oligodendrocytes. [18]

In human postmortem oligodendrocytes from people with MSA, higher TLR2 levels were tied to lower expression of a key myelin gene marker (MBP), supporting a connection between this immune-related pathway and weakened myelin programs in these cells. The same relationship was not seen in Parkinson's disease tissue in this report, which the authors presented as a potential MSA-relevant difference needing more confirmation. [18]

Another preclinical line of work tested vaccines designed to trigger antibodies against the specific folded shape of alpha-synuclein fibrils. In a synucleinopathy mouse model challenged with alpha-synuclein fibrils, vaccinated mice lived longer, and their antibodies recognized alpha-synuclein fibrils and brain tissue from MSA and other synuclein disorders. [19]

A separate postmortem study examined the choroid plexus (a structure involved in producing cerebrospinal fluid) across several brain diseases including MSA. Larger choroid plexus epithelial cells tended to contain more of a mitochondrial marker (Tom20), suggesting these cells may undergo metabolic remodeling in neurodegenerative conditions, although the small number of MSA samples meant the study could not reliably compare disease groups. [20]

For patients and caregivers, these papers mainly add background on what may be happening inside the brain in MSA: how alpha-synuclein may interact with oligodendrocytes and immune-like signaling (TLR2) in ways that relate to myelin health, and how other brain cell types may show metabolic changes in neurodegeneration. The intervention results were in mice and lab systems rather than people, so they do not show that any specific approach will help patients now. Key uncertainties include whether the same pathways are major drivers of disease in living people with MSA, which cell types matter most, and which measurable markers could track these processes over time.

Across these papers, non-movement symptoms stood out as important in multiple system atrophy (MSA), especially different types of pain that can affect sleep and daily comfort. At the same time, when researchers looked across many brain disorders using a specific balance eye-reflex test, MSA appeared to have a low rate of abnormal results compared with several other conditions, though estimates were uncertain because studies differed. [21] [22]

In a web-based survey study of 157 people with self-reported MSA, the most commonly reported pain types over the prior month were nocturnal pain (73%), musculoskeletal pain (63%), and fluctuation-related pain (62%). The same survey also highlighted MSA-related pain sources such as "coat-hanger" neck/shoulder pain when standing (59%), cold hands or feet (48%), and painful bruises from falls (44%), suggesting pain in MSA may come from more than one body system. [21]

When the survey results were compared with historical groups, musculoskeletal pain was reported less often in MSA than in Parkinson's disease, while orofacial pain was reported more often in MSA than in Parkinson's disease. The authors noted that the questionnaire used was designed for Parkinson's disease and was not validated specifically for MSA, so the exact percentages should be interpreted cautiously. [21]

A systematic review and meta-analysis pooled results from 45 studies using the video head impulse test (a test of the vestibulo-ocular reflex, which helps keep vision steady during head movement). Across many neurological conditions, about 48% had vestibular dysfunction, while the pooled estimate for MSA, based on two studies, was 5%. [22]

One case report described a 78-year-old woman with cerebellar-type MSA who developed posterior reversible encephalopathy syndrome (PRES), a brain condition seen on MRI that can occur with severe blood pressure changes. Her symptoms improved back to baseline after acute blood pressure control over about a week, and the authors discussed how MSA-related autonomic problems and a cancer drug (lenalidomide) might have contributed. This report describes one person and cannot show how common this complication is in MSA. [23]

For patients and caregivers, this set of studies reinforces that symptoms beyond movement, especially pain (including night pain, neck/shoulder pain when upright, and pain linked to falls), are frequently reported in MSA and can be a major part of the day-to-day experience. The balance-test review provides background that one specific vestibular reflex test is often abnormal in many brain disorders but was reported as rarely abnormal in MSA, and it remains unclear how well that test matches real-world dizziness or imbalance in MSA because study methods varied. The single PRES case mainly serves as awareness that sudden confusion or headache in the setting of very high blood pressure can have specific causes, but it does not indicate typical risk for most people with MSA.